Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals names new president
Mr Emmens has been a Vertex director since 2004, and previously served as CEO of Astra Merck, and of Shire, where he continues as chairman. Dr Boger, who
Mr Emmens has been a Vertex director since 2004, and previously served as CEO of Astra Merck, and of Shire, where he continues as chairman. Dr Boger, who
Internationally, the company is in the process of restructuring its sales and marketing business units in four countries in order to eliminate direct selling infrastructure costs. The company
US-based BioMarin Pharmaceutical has received marketing approval from ANVISA, Brazil’s National Health Surveillance Agency, for Naglazyme for the treatment of patients with mucopolysaccharidosis VI. Naglazyme was approved by
“While the economic and capital markets outlook for 2009 remains uncertain, the regenerative medicine and stem cell sectors have gained significant momentum and exposure since the beginning of
Ablynx, a developer of antibody-derived therapeutic proteins, has announced that it will receive milestone payments totaling E3m from Boehringer Ingelheim triggered as part of its strategic alliance for
This decision follows a successful end-of-Phase II meeting with the FDA, held on January 30, 2009. Algeta began enrolling patients for its global Phase III Alsympca study in
As previously reported, 29 of 109 evaluable patients, or 27%, achieved a response as assessed by central independent oncology review, which is the primary endpoint of the trial.
The objective of the first part of the program was to acquire the set of Altropane images which will be used to train expert readers for the Phase
For the past five months, Mr Cuesta has been overseeing the region in an acting capacity. Mr Cuesta joined the company in August 2005 as country director for
Christopher Menard, currently Phase Forward’s vice president of finance, will succeed Weismann as CFO at that time. After June 1, 2009 Weismann will serve in a part-time capacity